INTS
- Intensity Therapeutics, Inc.
()
Overview
Company Summary
Intensity Therapeutics, Inc. (INTS) is a biotechnology company focused on developing innovative cancer treatments. The company specializes in creating proprietary formulations of chemotherapy drugs that aim to enhance their effectiveness and minimize side effects.
INTS has developed a groundbreaking technology called InSitroCide� that enables the direct injection of its drug candidates into tumors. This approach allows for the targeted delivery of chemotherapeutic agents directly to cancer cells, while sparing healthy tissues from the toxic effects of traditional systemic chemotherapy.
By leveraging their proprietary drug-delivery technology, Intensity Therapeutics aims to provide more effective and well-tolerated cancer treatments. The company's approach has the potential to improve outcomes for patients across various cancer types, including solid tumors that have been challenging to treat with current therapies.
Furthermore, INTS is actively engaged in preclinical and clinical research to evaluate the safety and efficacy of its drug candidates. The company collaborates with academic institutions, research organizations, and clinical centers to advance the development of its innovative therapies.
In summary, Intensity Therapeutics, Inc. is a biotech company that specializes in creating targeted cancer treatments using its proprietary drug delivery technology. Through their innovative approach, they aim to improve patient outcomes and revolutionize the field of cancer therapeutics.